New data from Novo Nordisk’s Phase III ESSENCE study of semaglutide in non-alcoholic steatohepatitis (NASH) unveiled at the American Association for the Study of Liver Disease conference on 19 November showed that the GLP-1 agonist performed better than Madrigal’s Rezdiffra (resmetirom), the only approved NASH drug, in an analysis combining outcomes on the two primary endpoints, reduction of liver fibrosis and resolution of NASH.
Novo Nordisk’s Semaglutide Tops Madrigal’s Rezdiffra In NASH
Greater Combined Effect Seen In Phase III Trials
The firm revealed that an analysis of its Phase III ESSENCE trial combining fibrosis reduction and NASH resolution showed a higher effect over placebo than in Madrigal’s pivotal trial.
More from Conferences
• By
Finding a balance between out-licensing, refocusing on internal strengths and addressing unmet needs were identified at a recent Shanghai conference as some of the key strategies for Chinese biopharma firms looking to truly globalize.
• By
Nauman Shah, head of business development for J&J Innovation, sat down at the BIO CEO & Investor Conference to talk about his trip to China and the state of the biotech scene there.
• By
CEO Mike Exton talked to Scrip about moving the company forward after a disappointingly disruptive 2024.
• By
The founder and director of City Therapeutics and founding CEO of Alnylam discussed pressing issues facing the biotech sector in a fireside chat at the recent BIO CEO & Investor Conference.
More from Alimentary/Metabolic
• By
The Belgian firm banks nearly €77.7m to push its Charcot-Marie-Tooth to proof-of-concept.
• By
The company sees potential for the GLP-1/glucagon receptor dual agonist in MASH as well as alcohol-related liver disease as hopes to move pemvidutide into Phase III in obesity with a partner.
• By
Evaluate Pharma’s top 10 list of unpartnered mid-stage obesity assets shows that few credible challengers to Novo’s Wegovy and Lilly’s Zepbound remain available.